This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-0676v1 69/3/940    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Trédan, O. Articles by Tannock, I. F. Search for Related Content PubMed PubMed Citation Articles by Trédan, O. Articles by Tannock, I. F.

The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of Mitoxantrone

¹ Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto; ² Division of Applied Molecular Oncology, Ontario Cancer Institute, Toronto, Ontario, Canada and ³ Novacea, Inc., South San Francisco, California

Requests for reprints: Ian F. Tannock, Princess Margaret Hospital, Suite 5-208, 610 University Avenue, Toronto, ON M5G 2M9, Canada. Phone: 416-946-2245; Fax: 416-946-4563; E-mail: ian.tannock{at}uhn.on.ca.

Key Words: solid tumors • drug penetration • mitoxantrone • AQ4N • hypoxia

Hypoxic tumor cells are likely to be resistant to conventional chemotherapy, in large part because many anticancer drugs are unable to penetrate into poorly oxygenated tumor tissue. Here, we used quantitative immunofluorescence to study the distribution of mitoxantrone and AQ4N in tumor tissue. AQ4N is a prodrug activated under hypoxic conditions to AQ4, which is structurally similar to mitoxantrone and inhibits topoisomerase II. We characterized the penetration of mitoxantrone and AQ4N/AQ4 through multilayered cell cultures (MCC) and in relation to blood vessels and hypoxic regions in human tumor xenografts. We also studied tumor growth delay after treatment with each agent alone and with the combination. In both MCC and xenografts, mitoxantrone is taken up by proximal cells and penetrates slowly to distant regions. In contrast, AQ4N rapidly penetrates MCC and tumor tissue in vivo, and AQ4N (or its reduced form AQ4) is detected at high concentration within hypoxic regions. The targeting of mitoxantrone to oxygenated regions and AQ4N/AQ4 to hypoxic tumor regions results in effective drug exposure over the entire tumor after combined treatment and increases tumor growth delay compared with either drug alone. The combination of a clinically used anticancer drug with limited tissue penetration and a structurally related drug activated in regions of tumor hypoxia is an effective strategy to overcome chemoresistance due to the tumor microenvironment. This study supports clinical evaluation of AQ4N in combination with conventional anticancer agents, such as mitoxantrone. [Cancer Res 2009;69(3):940–7]

This article has been cited by other articles:

				K. J. Williams, M. R. Albertella, B. Fitzpatrick, P. M. Loadman, S. D. Shnyder, E. C. Chinje, B. A. Telfer, C. R. Dunk, P. A. Harris, and I. J. Stratford In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts Mol. Cancer Ther., December 1, 2009; 8(12): 3266 - 3275. [Abstract] [Full Text] [PDF]